Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...  Decision Resources Group finds that the vascular access device market ... India and China ... to the size of the United States ... much faster growth as a result of strong economic expansion, improving ... findings from Decision Resources Group,s coverage of the BRIC vascular access ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/20/2014)... August 20, 2014 WriteResult®, a leading ... that it has expanded its myPROpad™ ePRO tablet with ... one of the most widely used and well-respected ... health status. The EQ-5D is used during clinical trials ... measure that can be used to demonstrate Health-Related Quality ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... 29 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the ... and Earth Technology Development Corp. Ltd.,("China RainEarth") attended the ... , A good marketing strategy ... products. In the forum, participants explored various marketing,strategies and ...
... Calif., June 29 Kornberg Associates | Architects ( ... to design a new Cognitive & Neurobiological Imaging Center. ... The firm has worked with Stanford University since ... years, one of which is the two-story, 32,000 square-foot office ...
... Hutchinson Cancer Research Center board of trustees today announced that ... in June 2010. Hartwell, a recipient of the 2001 Nobel ... of the Hutchinson Center since 1997. , , ... of the Center for 12 years. It,s time for new ...
Cached Biology Technology:RainEarth (RNER) Continues to Expand its Marketing Force in China 2RainEarth (RNER) Continues to Expand its Marketing Force in China 3Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010 2
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million infants, ... researchers at the University of Massachusetts Medical School, have ... can be successfully implemented across public health newborn screening ... the Aug. 20 issue of the Journal of ... the rate of SCID in newborns is higher than ...
(Date:8/20/2014)... National Institutes of Health has awarded the Oklahoma Medical ... its research on anthrax and the bacteria,s effects on ... Coggeshall, Ph.D., and his colleagues have studied the human ... Cooperative Centers for Human Immunology. The original funding came ... on the heels of the terrorist attacks of Sept. ...
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... rearrangement hotspots has its most recent addition in a ... of California San Diego. The study, published on ... are indeed rearrangement hotspots in the human genome. ... for analyzing complex rearrangements (including transpositions) which demonstrates that ...
... TEMPE, Ariz. -- Anyone who has thrown a backyard barbecue ... than buns eight hot dogs per pack versus 10 ... weenie roasts are hot-dog limited the extra buns are ... limiting factors are a cornerstone of natural ecology, where phosphorus ...
... years, researchers have suspected there must be a natural ... body and could be harnessed to develop more effective ... Currently, drugs that lower sodium levels all have serious ... at Cornell and the Boyce Thompson Institute for Plant ...
Cached Biology News:At the root of nutrient limitation, ecosystems are not as different as they seem 2At the root of nutrient limitation, ecosystems are not as different as they seem 3Researchers' discovery may lead to hypertension treatment 2
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Biology Products: